Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY Voorraadrapport

Marktkapitalisatie: US$34.8b

Alnylam Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Alnylam Pharmaceuticals is Yvonne Greenstreet, benoemd in Jan2022, heeft een ambtstermijn van 2.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.90M, bestaande uit 11% salaris en 89% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.039% van de aandelen van het bedrijf, ter waarde $ 13.52M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 9 jaar.

Belangrijke informatie

Yvonne Greenstreet

Algemeen directeur

US$8.9m

Totale compensatie

Percentage CEO-salaris11.0%
Dienstverband CEO2.8yrs
Eigendom CEO0.04%
Management gemiddelde ambtstermijn2.8yrs
Gemiddelde ambtstermijn bestuur9yrs

Recente managementupdates

Recent updates

Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch

Oct 27

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Sep 12
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Alnylam: HELIOS-B Success Priced In Already

Aug 30

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Aug 04
Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Aug 02
Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23
Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo

Oct 07

Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market

Sep 26

Analyse CEO-vergoeding

Hoe is Yvonne Greenstreet's beloning veranderd ten opzichte van Alnylam Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$332m

Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$332m

Dec 31 2023US$9mUS$976k

-US$440m

Sep 30 2023n/an/a

-US$510m

Jun 30 2023n/an/a

-US$1b

Mar 31 2023n/an/a

-US$1b

Dec 31 2022US$5mUS$850k

-US$1b

Sep 30 2022n/an/a

-US$1b

Jun 30 2022n/an/a

-US$981m

Mar 31 2022n/an/a

-US$893m

Dec 31 2021US$9mUS$619k

-US$853m

Sep 30 2021n/an/a

-US$838m

Jun 30 2021n/an/a

-US$887m

Mar 31 2021n/an/a

-US$876m

Dec 31 2020US$3mUS$622k

-US$858m

Sep 30 2020n/an/a

-US$891m

Jun 30 2020n/an/a

-US$846m

Mar 31 2020n/an/a

-US$886m

Dec 31 2019US$3mUS$571k

-US$886m

Sep 30 2019n/an/a

-US$821m

Jun 30 2019n/an/a

-US$858m

Mar 31 2019n/an/a

-US$802m

Dec 31 2018US$3mUS$540k

-US$761m

Sep 30 2018n/an/a

-US$692m

Jun 30 2018n/an/a

-US$570m

Mar 31 2018n/an/a

-US$525m

Dec 31 2017US$985kUS$504k

-US$491m

Compensatie versus markt: De totale vergoeding ($USD 8.90M ) Yvonne } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.88M ).

Compensatie versus inkomsten: De vergoeding van Yvonne is gestegen terwijl het bedrijf verliesgevend is.

CEO

Yvonne Greenstreet (61 yo)

2.8yrs

Tenure

US$8,895,670

Compensatie

Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. Sh...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Yvonne Greenstreet
CEO & Director2.8yrsUS$8.90m0.039%
$ 13.5m
Jeffrey Poulton
CFO & Executive VP5.3yrsUS$3.22m0.016%
$ 5.7m
Akshay Vaishnaw
Chief Innovation Officer & Member of the Scientific Advisory Board1.1yrsUS$3.32m0.018%
$ 6.3m
Pushkal Garg
Chief Medical Officer10.1yrsUS$3.23m0.0090%
$ 3.1m
Tolga Tanguler
Executive VP & Chief Commercial Officer3.8yrsUS$2.87m0.0054%
$ 1.9m
Timothy Maines
Chief Technical Operations & Quality Officer1.8yrsgeen gegevensgeen gegevens
Kevin Fitzgerald
Senior VP5.5yrsgeen gegevens0.010%
$ 3.6m
Piyush Sharma
Chief Ethics & Compliance Officer2.2yrsgeen gegevensgeen gegevens
Robert Hesslein
Chief Legal Officer & Corporate Secretaryless than a yeargeen gegevensgeen gegevens
Christine Lindenboom
Chief Corporate Communications Officerno datageen gegevensgeen gegevens
Evan Lippman
Chief Corporate Development & Strategy Officer2.2yrsgeen gegevensgeen gegevens
Kelley Boucher
Chief Human Resource Officer5.5yrsgeen gegevensgeen gegevens

2.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ALNY wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Yvonne Greenstreet
CEO & Director3.1yrsUS$8.90m0.039%
$ 13.5m
Akshay Vaishnaw
Chief Innovation Officer & Member of the Scientific Advisory Boardno dataUS$3.32m0.018%
$ 6.3m
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board9.1yrsgeen gegevensgeen gegevens
Peter Kellogg
Independent Director1.7yrsUS$658.72k0%
$ 0
Paul Schimmel
Member of the Scientific Advisory Boardno dataUS$516.04kgeen gegevens
David E. Pyott
Independent Director8.9yrsUS$477.21k0.022%
$ 7.6m
Phillip Sharp
Co-Founder22.4yrsUS$502.21k0.21%
$ 72.0m
Amy W. Schulman
Independent Chair of the Board & Lead Independent Director10.3yrsUS$531.36k0.0065%
$ 2.3m
Markus Stoffel
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
David Bartel
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Dennis Ausiello
Member of the Scientific Advisory Board & Independent Director12.6yrsUS$477.21k0.0028%
$ 981.9k
Colleen Reitan
Independent Director6.4yrsUS$489.15k0%
$ 0

9.0yrs

Gemiddelde duur

69.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALNY wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).